[go: up one dir, main page]

MX2009008734A - Gamma lactamas para el tratamiento de glaucoma o hipertension intraocular. - Google Patents

Gamma lactamas para el tratamiento de glaucoma o hipertension intraocular.

Info

Publication number
MX2009008734A
MX2009008734A MX2009008734A MX2009008734A MX2009008734A MX 2009008734 A MX2009008734 A MX 2009008734A MX 2009008734 A MX2009008734 A MX 2009008734A MX 2009008734 A MX2009008734 A MX 2009008734A MX 2009008734 A MX2009008734 A MX 2009008734A
Authority
MX
Mexico
Prior art keywords
lactams
glaucoma
gamma
treatment
intraocular pressure
Prior art date
Application number
MX2009008734A
Other languages
English (en)
Inventor
David W Old
Vinh X Ngo
Wha Bin Im
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2009008734A publication Critical patent/MX2009008734A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos terapéuticos, composiciones, métodos, y medicamentos relacionados a éstos.
MX2009008734A 2007-02-15 2008-02-08 Gamma lactamas para el tratamiento de glaucoma o hipertension intraocular. MX2009008734A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89018107P 2007-02-15 2007-02-15
PCT/US2008/053386 WO2008100809A1 (en) 2007-02-15 2008-02-08 Gamma-lactams for the treatment of glaucoma or elevated intraocular pressure

Publications (1)

Publication Number Publication Date
MX2009008734A true MX2009008734A (es) 2009-08-25

Family

ID=39511007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008734A MX2009008734A (es) 2007-02-15 2008-02-08 Gamma lactamas para el tratamiento de glaucoma o hipertension intraocular.

Country Status (12)

Country Link
US (1) US8362054B2 (es)
EP (1) EP2118094B1 (es)
JP (1) JP5566696B2 (es)
KR (1) KR20090109587A (es)
CN (1) CN101657445B (es)
AU (1) AU2008216499B2 (es)
BR (1) BRPI0807600A2 (es)
CA (1) CA2678191A1 (es)
ES (1) ES2404169T3 (es)
MX (1) MX2009008734A (es)
NZ (1) NZ598945A (es)
WO (1) WO2008100809A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2215084B1 (en) * 2007-10-23 2016-09-28 Allergan, Inc. Therapeutic substituted lactams
KR20240019753A (ko) * 2021-03-08 2024-02-14 아비오닉스 파마 에스에이 간 질환을 치료하는 데 유용한 화합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE315022T1 (de) * 2001-07-16 2006-02-15 Hoffmann La Roche Prostaglandinanaloga als ep4-rezeptoragonisten
KR100437972B1 (ko) * 2001-10-27 2004-07-02 한국과학기술연구원 피롤리디논 유도체, 이의 제조 방법 및 이를 포함하는제약 조성물
JP4547912B2 (ja) * 2002-03-05 2010-09-22 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7419999B2 (en) * 2002-06-10 2008-09-02 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
AU2003275838A1 (en) * 2002-10-25 2004-05-13 Beunard, Jean-Luc Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US20080249028A1 (en) 2005-03-09 2008-10-09 Roger Williams Hospital Thyrotropin-Releasing Hormone Analogs and Method of Use
RU2412933C2 (ru) * 2005-03-10 2011-02-27 Аллерган, Инк. Замещенные гамма-лактамы в качестве терапевтических агентов
WO2007109578A2 (en) * 2006-03-20 2007-09-27 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists

Also Published As

Publication number Publication date
KR20090109587A (ko) 2009-10-20
JP2010519208A (ja) 2010-06-03
WO2008100809A1 (en) 2008-08-21
CN101657445B (zh) 2013-06-05
AU2008216499B2 (en) 2014-04-17
CN101657445A (zh) 2010-02-24
BRPI0807600A2 (pt) 2014-07-22
CA2678191A1 (en) 2008-08-21
AU2008216499A1 (en) 2008-08-21
EP2118094A1 (en) 2009-11-18
US20100168189A1 (en) 2010-07-01
ES2404169T3 (es) 2013-05-24
US8362054B2 (en) 2013-01-29
EP2118094B1 (en) 2013-04-17
NZ598945A (en) 2013-08-30
JP5566696B2 (ja) 2014-08-06

Similar Documents

Publication Publication Date Title
MX2009001062A (es) Agonistas de ep2.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
WO2009129246A3 (en) Compositions and methods for preparing and using same
MY172372A (en) Compositions and methods for lowering triglycerides
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
MY159244A (en) Method of reducing intraocular pressure in humans
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
TW200738651A (en) Cyclohexyl sulfonamide derivatives
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
AU2009331669A8 (en) Dihydropyridone amides as P2X7 modulators
GEP20156224B (en) Therapeutic agent for mood disorders
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
MY150931A (en) Substituted oxazolidinones and their use
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
WO2010012745A3 (en) Benzimidazoles
WO2009078978A3 (en) Compositions containing polyglycidol-based polymers and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration